Meeting
2023 ASCO Annual Meeting
Belzutifan treatment of Von Hippel-Lindau (VHL) related central nervous system (CNS) hemangioblastomas (HBs): A single institution experience.
Authors
Othon Iliopoulos
Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA
Othon Iliopoulos , Otto Rapalino , Frederick G. Barker II, Jean-Valery Coumans , Pamela Jones , Lauren Bear , Eumorphia Konstantakou , Christina Orr , Maura Mahar , Brian Nahed
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Non-Glioma
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2078)
DOI
10.1200/JCO.2023.41.16_suppl.2078
Abstract #
2078
Poster Bd #
435
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Phase II study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).
First Author: Othon Iliopoulos
Poster
2023 ASCO Annual Meeting
Real-world outcomes and safety in patients with VHL associated tumors receiving belzutifan.
First Author: Anusha Chidharla
Poster
2023 ASCO Genitourinary Cancers Symposium
Burden of surgeries and surgical complications in patients with Von Hippel Lindau (VHL) disease before and after treatment with belzutifan.
First Author: Lin Wang
Poster
2021 ASCO Annual Meeting
Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).
First Author: Ramaprasad Srinivasan